Skip to main content

Table 3 Comparison of rates of improvement in patients with pulmonary Mycobacterium avium complex disease between the control and levofloxacin (LVFX) groups

From: Retrospective investigation of combination therapy with clarithromycin and levofloxacin for pulmonary Mycobacterium avium complex disease

Evaluation Group Follow-up period (months)
1 3 6 12
Culture examination Control 33/57 (58 %) 43/52 (83 %) 38/48 (79 %) 35/44 (80 %)
LVFX 9/18 (50 %) 4/8 (50 %) 4/6 (67 %) 2/3 (67 %)
Smear examination
   Ziehl–Neelsen’s staining Control 44/57 (77 %) 47/52 (90 %) 44/48 (92 %) 36/43 (84 %)
LVFX 11/18 (61 %) 5/8 (63 %) 5/6 (83 %) 2/3 (67 %)
   Fluorescence microscopy Control 41/57 (72 %) 43/52 (83 %) 44/48 (92 %) 38/44 (86 %)
LVFX 10/18 (56 %) *3/8 (38 %) 4/6 (67 %) 2/3 (67 %)
  1. * A P-value of less than 0.05 was considered statistically significant